Sustiva

Country: European Union

Language: Swedish

Source: EMA (European Medicines Agency)

Active ingredient:

efavirenz

Available from:

Bristol-Myers Squibb Pharma EEIG

ATC code:

J05AG03

INN (International Name):

efavirenz

Therapeutic group:

Antivirala medel för systemisk användning

Therapeutic area:

HIV-infektioner

Therapeutic indications:

Sustiva indikeras i antiviral kombinationsbehandling av mänskliga-immunbrist-virus-1 (HIV-1)-infekterade vuxna, ungdomar och barn tre år och äldre. Sustiva har inte undersökts tillräckligt på patienter med avancerad HIV-sjukdom, nämligen hos patienter med CD4 räknar < 50 celler/mm3, eller efter ett misslyckande av proteas-hämmare (PI)-innehåller regimer. Även om korsresistens av efavirenz med PIs har inte dokumenterats, finns det för närvarande inte finns tillräckliga data om effekten av efterföljande användning av PI-baserad kombinationsterapi efter misslyckandet med regimer som innehåller Sustiva.

Product summary:

Revision: 48

Authorization status:

auktoriserad

Authorization date:

1999-05-28

Patient Information leaflet

                                1/1
EU-NUMMER
LÄKEMEDLETS
NAMN
STYRKA
LÄKEMEDELSFORM
ADMINISTRERINGSSÄTT
FÖRPACKNING
FÖRPACKNINGSSTORLEK
EU/1/99/110/001
Sustiva
50 mg
Hård kapsel
Oral användning
burk (HDPE)
30 kapslar
EU/1/99/110/002
Sustiva
100 mg
Hård kapsel
Oral användning
burk (HDPE)
30 kapslar
EU/1/99/110/003
Sustiva
200 mg
Hård kapsel
Oral användning
burk (HDPE)
90 kapslar
EU/1/99/110/004
Sustiva
200 mg
Hård kapsel d
Oral användning
blister (alu/PVC)
42 kapslar
EU/1/99/110/008
Sustiva
600 mg
Filmdragerad tablett
Oral användning
burk (HDPE)
30 tabletter
EU/1/99/110/009
Sustiva
600 mg
Filmdragerad tablett
Oral användning
blister (alu)
30 tabletter
EU/1/99/110/010
Sustiva
600 mg
Filmdragerad tablett
Oral användning
blister (alu)
90 tabletter
Läkemedlet är inte längre godkänt för försäljning
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1/1
EU-NUMMER
LÄKEMEDLETS
NAMN
STYRKA
LÄKEMEDELSFORM
ADMINISTRERINGSSÄTT
FÖRPACKNING
FÖRPACKNINGSSTORLEK
EU/1/99/110/001
Sustiva
50 mg
Hård kapsel
Oral användning
burk (HDPE)
30 kapslar
EU/1/99/110/002
Sustiva
100 mg
Hård kapsel
Oral användning
burk (HDPE)
30 kapslar
EU/1/99/110/003
Sustiva
200 mg
Hård kapsel
Oral användning
burk (HDPE)
90 kapslar
EU/1/99/110/004
Sustiva
200 mg
Hård kapsel d
Oral användning
blister (alu/PVC)
42 kapslar
EU/1/99/110/008
Sustiva
600 mg
Filmdragerad tablett
Oral användning
burk (HDPE)
30 tabletter
EU/1/99/110/009
Sustiva
600 mg
Filmdragerad tablett
Oral användning
blister (alu)
30 tabletter
EU/1/99/110/010
Sustiva
600 mg
Filmdragerad tablett
Oral användning
blister (alu)
90 tabletter
Läkemedlet är inte längre godkänt för försäljning
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 14-03-2024
Public Assessment Report Public Assessment Report Bulgarian 26-01-2018
Patient Information leaflet Patient Information leaflet Spanish 14-03-2024
Public Assessment Report Public Assessment Report Spanish 26-01-2018
Patient Information leaflet Patient Information leaflet Czech 14-03-2024
Public Assessment Report Public Assessment Report Czech 26-01-2018
Patient Information leaflet Patient Information leaflet Danish 14-03-2024
Public Assessment Report Public Assessment Report Danish 26-01-2018
Patient Information leaflet Patient Information leaflet German 14-03-2024
Public Assessment Report Public Assessment Report German 26-01-2018
Patient Information leaflet Patient Information leaflet Estonian 14-03-2024
Public Assessment Report Public Assessment Report Estonian 26-01-2018
Patient Information leaflet Patient Information leaflet Greek 14-03-2024
Public Assessment Report Public Assessment Report Greek 26-01-2018
Patient Information leaflet Patient Information leaflet English 14-03-2024
Public Assessment Report Public Assessment Report English 26-01-2018
Patient Information leaflet Patient Information leaflet French 14-03-2024
Public Assessment Report Public Assessment Report French 26-01-2018
Patient Information leaflet Patient Information leaflet Italian 14-03-2024
Public Assessment Report Public Assessment Report Italian 26-01-2018
Patient Information leaflet Patient Information leaflet Latvian 14-03-2024
Public Assessment Report Public Assessment Report Latvian 26-01-2018
Patient Information leaflet Patient Information leaflet Lithuanian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 14-03-2024
Public Assessment Report Public Assessment Report Lithuanian 26-01-2018
Patient Information leaflet Patient Information leaflet Hungarian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 14-03-2024
Public Assessment Report Public Assessment Report Hungarian 26-01-2018
Patient Information leaflet Patient Information leaflet Maltese 14-03-2024
Public Assessment Report Public Assessment Report Maltese 26-01-2018
Patient Information leaflet Patient Information leaflet Dutch 14-03-2024
Public Assessment Report Public Assessment Report Dutch 26-01-2018
Patient Information leaflet Patient Information leaflet Polish 14-03-2024
Public Assessment Report Public Assessment Report Polish 26-01-2018
Patient Information leaflet Patient Information leaflet Portuguese 14-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 14-03-2024
Public Assessment Report Public Assessment Report Portuguese 26-01-2018
Patient Information leaflet Patient Information leaflet Romanian 14-03-2024
Public Assessment Report Public Assessment Report Romanian 26-01-2018
Patient Information leaflet Patient Information leaflet Slovak 14-03-2024
Public Assessment Report Public Assessment Report Slovak 26-01-2018
Patient Information leaflet Patient Information leaflet Slovenian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 14-03-2024
Public Assessment Report Public Assessment Report Slovenian 26-01-2018
Patient Information leaflet Patient Information leaflet Finnish 14-03-2024
Public Assessment Report Public Assessment Report Finnish 26-01-2018
Patient Information leaflet Patient Information leaflet Norwegian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 14-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 14-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 14-03-2024
Patient Information leaflet Patient Information leaflet Croatian 14-03-2024
Public Assessment Report Public Assessment Report Croatian 26-01-2018

Search alerts related to this product

View documents history